NCT06569147View on ClinicalTrials.gov

Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2029

Conditions
AL Amyloidosis
Interventions
DRUG

Elranatamab

Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle

Trial Locations (1)

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER